- Home
- MARPS vs TOVX Comparison
MARPS vs TOVX Comparison
Compare MARPS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | TOVX |
|---|---|---|
| Founded | 1956 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 10.1M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | MARPS | TOVX |
|---|---|---|
| Price | $4.46 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 2.3K | ★ 452.9K |
| Earning Date | 02-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.05 | $0.16 |
| 52 Week High | $6.49 | $0.86 |
Technical Indicators
Market Signals| Indicator | MARPS | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 56.45 |
| Support Level | $4.80 | $0.22 |
| Resistance Level | $4.86 | $0.26 |
| Average True Range (ATR) | 0.05 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 56.86 | 65.31 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.